Active secondary progressive MS is defined as people experiencing relapses or showing signs of inflammation in MRI scans
This is exciting news, as siponimod is the first oral drug to be licensed for secondary progressive MS in Europe. Secondary progressive MS has an impact on all aspects of people’s lives – physical, emotional, social and economic - affecting not only the person diagnosed, but also their families. We hope that the availability of a new treatment will lead to a renewed focus on the needs of all people with progressive MS and improve their access to services.
- David Martin, Chief Executive Officer, MS Trust
As someone with SPMS I am delighted that at last a treatment has been licensed for people like myself. For too long we have been excluded from services and been ignored, this decision provides an opportunity to slow our disease progression with the possibility of improving our quality of life immeasurably. Roll on NICE approval.
- Caroline Smith
The next step in the approval process is for the European Commission to grant the licence, taking into the consideration the EMA's recommendation. Siponimod will then be appraised by NICE and SMC to decide whether it is a cost-effective treatment for the NHS.
NICE has already started the appraisal process for siponimod and a decision is expected in May 2020. The MS Trust is responded to the appraisal. If NICE approves the use of siponimod, it could be available on the NHS by the end of 2020.
Siponimod is taken as a tablet, once a day.
In clinical trials for secondary progressive MS, siponimod reduced the risk of disability progression by 26% compared to placebo. Further analysis indicated a 37% reduction in the risk of progression for those with active SPMS (defined as those who had relapsed in the two years prior to starting the trial).
In clinical trials, low white blood cell count, increased liver enzyme levels, slower heart rate when starting treatment, macular oedema (swelling in the back of the eye affecting vision), high blood pressure, shingles, and convulsions occurred more frequently with siponimod than with placebo.
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 Oct 2021 - 00:00
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 Sep 2021 - 00:00
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 Aug 2021 - 00:00
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting multiple sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.